|
WO2021062317A1
|
|
Extracellular vesicle compositions
|
|
WO2021062290A1
|
|
Methods of producing extracellular vesicles
|
|
WO2021062060A1
|
|
Sting agonist comprising exosomes combined with il-12 displaying exosomes for treating a tumour
|
|
WO2021062057A1
|
|
Exogenous loading of exosomes via lyophilization
|
|
WO2021062058A1
|
|
Sting agonist comprising exosomes for treating neuroimmunological disorders
|
|
WO2021030781A1
|
|
Extracellular vesicles with antisense oligonucleotides targeting kras
|
|
WO2021030780A1
|
|
Extracellular vesicle-aso constructs targeting cebp/beta
|
|
WO2021030773A1
|
|
Extracellular vesicle-nlrp3 antagonist
|
|
WO2021030777A1
|
|
Extracellular vesicle linked to molecules and uses thereof
|
|
WO2021030768A1
|
|
Extracellular vesicles with stat3-antisense oligonucleotides
|
|
WO2021030776A1
|
|
Extracellular vesicle-aso constructs targeting stat6
|
|
WO2021003425A1
|
|
Methods of inducing hematopoiesis
|
|
WO2021003445A1
|
|
Extracellular vesicles targeting t cells and uses thereof
|
|
WO2020214961A1
|
|
Methods of treating tuberculosis
|
|
WO2020215010A1
|
|
Compositions of exosomes and aav
|
|
WO2020191361A2
|
|
Extracellular vesicles for vaccine delivery
|
|
WO2020191369A1
|
|
Process for preparing extracellular vesicles
|
|
WO2020191377A1
|
|
Extracellular vesicle conjugates and uses thereof
|
|
WO2020163366A1
|
|
Treatment of cancer metastasis by targeting exosome proteins
|
|
WO2020163370A1
|
|
Membrane protein scaffolds for exosome engineering
|
